{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-100790","form_type":"8-K","ticker":null,"cik":"0001492674","company_name":"T2 Biosystems, Inc.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.642887+00:00","generated_at":"2026-06-03T18:45:36.722631+00:00","sec_items":["1.01","5.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"T2 Biosystems converts $15M of debt to equity; extends PIK interest option to Dec 2025","bullets":["$15M of term loans converted into 3,280,618 common shares and 17,160.48 Series A Convertible Preferred shares.","Each Series A share convertible into 100 common shares; outstanding loan principal reduced to ~$26.79M.","Consent and Amendment No. 10 extends PIK period through earlier of Dec 31, 2025 or default.","Change of Control definition amended to exclude stock acquisitions by CRG lenders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-100790","json":"https://secwatch.observer/filing/0001193125-24-100790.json","markdown":"https://secwatch.observer/filing/0001193125-24-100790.md","text":"https://secwatch.observer/filing/0001193125-24-100790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492674/000119312524100790/0001193125-24-100790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492674/000119312524100790/d786433d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:45:36.722631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e738ee35555469d4f5482a4914740157a5cf9a95","claim":"T2 Biosystems, Inc.: Filed a Certificate of Designation for Series A Convertible Preferred Stock, establishing its preferences, rights, and limitations (effective 2024-04-12).","evidence_excerpt":"On April 12, 2024, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Certificate of Designation ”) with the Secretary of State of the State of Delaware pursuant to the Securities Purchase Agreement.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312524100790/0001193125-24-100790-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-12"}],"fact_type":"governance_change"},{"claim_id":"8025d17c2690697a15e7398a88ec5a5e86d3ddf5","claim":"T2 Biosystems, Inc. entered into Securities Purchase Agreement with CRG Partners III L.P., CRG Partners III - Parallel Fund \"A\" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund \"B\" (Cayman) L.P. valued at $15.0 million (effective 2024-02-15).","evidence_excerpt":"The Exchange was completed pursuant to the Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated as of February 15, 2024, with CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312524100790/0001193125-24-100790-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"CRG Partners III L.P., CRG Partners III - Parallel Fund \"A\" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund \"B\" (Cayman) L.P."},{"label":"Value","value":"$15.0 million"},{"label":"Effective","value":"2024-02-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}